title: [Issues around diffuse glioma].
abstract: Progress in treating diffuse gliomas remains limited and is principally concerned with the confirmation that cystostatics as nitrosureum derivatives and temozolomide play a role in the treatment of these tumours. At molecular level, diffuse gliomas are a heterogeneous group of tumours. This seems to be an important explanation of why so far no important breakthrough in the treatment of these tumours has been achieved. It is thought that abnormal activation of various molecular signal systems working in parallel in the tumour cell are an important cause of the absence of efficacy of the targeted agents; the inhibition of only one target appears inadequate.
authors.affiliation: Daniel den Hoed Oncologisch Centrum, Erasmus MC, Afd. Neurologie/Neuro-oncologie, the Netherlands. m.vandenbent@erasmusmc.nl
authors.forename: Martin J
authors.initials: MJ
authors.lastname: van den Bent
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D005910:Glioma / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide